对清细胞癌晚期复发的预后因素的评估:一项机构研究
Diana Voskuil-Galoş1, Tudor Călinici2, Andra Piciu1,3
1Department of Medical Oncology, The Oncology Institute Prof. Dr. Ion Chiricuţă, Cluj-Napoca, Romania.
Frontiers in oncology
|October 22, 2024
概括
非转移性细胞癌 (nmRCC) 的晚期复发是常见的. 预后因素如IMDC得分和Fuhrman等级影响生存率,表明需要在手术后对患者进行延长的随访.
科学领域:
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 在瘤学瘤学.
- 腎臟病學 (nephrology) 是一種醫學專業.
背景情况:
- 一部分患有非转移性细胞癌 (nmRCC) 的患者经历了晚期复发,定义为经过切除术5年以上的转移性复发.
- 了解这些晚期复发的患病率和预后因素对于优化患者管理至关重要.
研究的目的:
- 评估罗马尼亚患者晚期复发的发病率,这些患者经过切除术后患有nmRCC.
- 确定临床病理学特征,作为晚期复发RCC的预后指标.
主要方法:
- 一项回顾性,单中心的观察性研究分析了51名患有清晰细胞nmRCC组织学的患者,这些患者接受了治疗性意图手术.
- 收集的数据包括无病生存率 (DFS),总生存率 (OS) 和与预后因素的相关性,如IMDC得分,NLR,瘤大小和Fuhrman核等级.
主要成果:
- 51%的患者复发,其中42%的患者在60个月后复发.
- DFS与IMDC得分,中性粒细胞与淋巴细胞比率 (NLR),瘤大小和Fuhrman核等级有显著的相关性.
- 整体存活率 (OS) 与IMDC得分和Fuhrman核等级相关.
结论:
- 局部RCC的晚期复发并不罕见,在初级瘤手术后需要延长的随访间隔.
- 特定的生物标志物,包括IMDC评分和Fuhrman核等级,是预测RCC患者生存结果的有价值的预后因素.
相关概念视频
Factors Affecting Renal Clearance: Renal Impairment
58
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
58
Cancer Survival Analysis
328
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
328


